Roche Pharma Research and Early Development, Roche Innovation Center Basel, 124 Grenzacherstrasse, 4058, Basel, Switzerland.
Honorary and Emerita Professor of Ophthalmology, Queens University of Belfast, Belfast, UK.
Eye (Lond). 2024 Dec;38(17):3243-3251. doi: 10.1038/s41433-024-03308-6. Epub 2024 Aug 28.
The natural history of neovascular age-related macular degeneration (nAMD) leads to scarring and loss of vision. Since the advent of anti-VEGF therapies, which are very effective for controlling exudation, large disciform scars are rarely encountered in the clinic. However long term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment. This means that additional mechanisms of action may be required to completely address this condition. To permit new treatments, a proper understanding of the clinical impact of fibrosis is required. This review is focused on clinical aspects of fibrosis and summarises recent data on biomarkers, prevalence, causes, consequences, and therapies, highlighting the most important and urgent topics to tackle in order to advance in the treatment of fibrosis.
新生血管性年龄相关性黄斑变性(nAMD)的自然病程可导致瘢痕形成和视力丧失。自抗血管内皮生长因子(VEGF)治疗问世以来,由于其对渗出的控制非常有效,临床上很少见到大的盘状瘢痕。然而,长期研究表明,尽管进行了最佳治疗,较小且不太严重的纤维化瘢痕仍很常见,并随时间而发展。这意味着可能需要其他作用机制来完全解决这种情况。为了允许新的治疗方法,需要正确了解纤维化的临床影响。本综述重点关注纤维化的临床方面,总结了生物标志物、患病率、病因、后果和治疗方面的最新数据,强调了为推进纤维化治疗需要解决的最重要和最紧迫的问题。